These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30133757)

  • 21. Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors.
    Liao CP; Liang M; Cohen MB; Flesken-Nikitin A; Jeong JH; Nikitin AY; Roy-Burman P
    Horm Cancer; 2010 Feb; 1(1):44-54. PubMed ID: 20631921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers.
    Hafeez BB; Fischer JW; Singh A; Zhong W; Mustafa A; Meske L; Sheikhani MO; Verma AK
    Cancer Prev Res (Phila); 2015 May; 8(5):375-86. PubMed ID: 25627799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
    Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
    Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
    Jiao J; Wang S; Qiao R; Vivanco I; Watson PA; Sawyers CL; Wu H
    Cancer Res; 2007 Jul; 67(13):6083-91. PubMed ID: 17616663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.
    Hill R; Song Y; Cardiff RD; Van Dyke T
    Cancer Res; 2005 Nov; 65(22):10243-54. PubMed ID: 16288012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
    Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
    Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SLUG is a direct transcriptional repressor of PTEN tumor suppressor.
    Uygur B; Abramo K; Leikina E; Vary C; Liaw L; Wu WS
    Prostate; 2015 Jun; 75(9):907-16. PubMed ID: 25728608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
    Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
    J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer.
    Wu RC; Young IC; Chen YF; Chuang ST; Toubaji A; Wu MY
    Nat Commun; 2019 Sep; 10(1):4332. PubMed ID: 31551414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype.
    Hong SW; Shin JS; Moon JH; Kim YS; Lee J; Choi EK; Ha SH; Lee DH; Chung HN; Kim JE; Kim KP; Hong YS; Lee JL; Lee WJ; Choi EK; Lee JS; Jin DH; Kim TW
    Apoptosis; 2014 May; 19(5):895-904. PubMed ID: 24652480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
    Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
    Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
    Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
    Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
    Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.
    Bastos DC; Ribeiro CF; Ahearn T; Nascimento J; Pakula H; Clohessy J; Mucci L; Roberts T; Zanata SM; Zadra G; Loda M
    J Pathol; 2021 Mar; 253(3):292-303. PubMed ID: 33166087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TIP5 primes prostate luminal cells for the oncogenic transformation mediated by
    Pietrzak K; Kuzyakiv R; Simon R; Bolis M; Bär D; Aprigliano R; Theurillat JP; Sauter G; Santoro R
    Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3637-3647. PubMed ID: 32024754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
    Karr JF; Kantor JA; Hand PH; Eggensperger DL; Schlom J
    Cancer Res; 1995 Jun; 55(11):2455-62. PubMed ID: 7538903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
    Fang J; Ding M; Yang L; Liu LZ; Jiang BH
    Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer.
    Svensson RU; Haverkamp JM; Thedens DR; Cohen MB; Ratliff TL; Henry MD
    Am J Pathol; 2011 Jul; 179(1):502-12. PubMed ID: 21703427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.